These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
15. Drug Insight: endothelin-receptor antagonists for pulmonary arterial hypertension in systemic rheumatic diseases. Humbert M; Simonneau G Nat Clin Pract Rheumatol; 2005 Dec; 1(2):93-101. PubMed ID: 16932638 [TBL] [Abstract][Full Text] [Related]
16. Endothelin receptor antagonists in the treatment of pulmonary arterial hypertension. Langleben D Clin Chest Med; 2007 Mar; 28(1):117-25, viii. PubMed ID: 17338931 [TBL] [Abstract][Full Text] [Related]
17. Severe hepatitis associated with sitaxentan and response to glucocorticoid therapy. Hoeper MM; Olsson KM; Schneider A; Golpon H Eur Respir J; 2009 Jun; 33(6):1518-9. PubMed ID: 19483056 [No Abstract] [Full Text] [Related]
18. Selective endothelin A receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease. Girgis RE; Frost AE; Hill NS; Horn EM; Langleben D; McLaughlin VV; Oudiz RJ; Robbins IM; Seibold JR; Shapiro S; Tapson VF; Barst RJ Ann Rheum Dis; 2007 Nov; 66(11):1467-72. PubMed ID: 17472992 [TBL] [Abstract][Full Text] [Related]
19. A review of sitaxsentan sodium in patients with pulmonary arterial hypertension. Waxman AB Vasc Health Risk Manag; 2007; 3(1):151-7. PubMed ID: 17583185 [TBL] [Abstract][Full Text] [Related]
20. Attenuation of pulmonary vascular hypertension and cardiac hypertrophy with sitaxsentan sodium, an orally active ET(A) receptor antagonist. Tilton RG; Munsch CL; Sherwood SJ; Chen SJ; Chen YF; Wu C; Block N; Dixon RA; Brock TA Pulm Pharmacol Ther; 2000; 13(2):87-97. PubMed ID: 10799286 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]